.Anavex Life Sciences’ lead asset has failed to significantly improve disease characteristics in a pediatric Rett syndrome trial, with the company pointing the blame toward a high placebo effect.The New York City-based biotech's stock cratered 30% since the data was shared earlier today, tumbling from $9.32 per share at market close Friday to $6.55 as of 10:30 a.m. ET.
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-96
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.95 |
Change
0.955(4.55%) |
Mkt cap ! $2.778B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.13 | $21.50 | $6.400M | 293.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 59 | $21.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.95 | 7 | 1 |
View Market Depth
| Last trade - 13.16pm 17/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |